Loading...
XLONTRX
Market cap52mUSD
Dec 27, Last price  
59.00GBP
1D
0.00%
1Q
9.26%
Jan 2017
187.80%
IPO
391.67%
Name

Tissue Regenix Group PLC

Chart & Performance

D1W1MN
XLON:TRX chart
P/E
—
P/S
179.32
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
43.15%
Rev. gr., 5y
20.48%
Revenues
29m
+48.43%
13,919000077,3950100,0001,162,1441,574,1835,233,00011,619,00013,033,00012,829,00014,357,55419,870,42829,493,000
Net income
-2m
L-21.71%
0000000-7,581,0000-10,675,645-9,221,000-8,186,000-6,973,000-9,709,000-3,484,320-2,187,890-1,713,000
CFO
1m
P
0000000-8,117,0000-10,697,000-9,739,000-6,766,000-7,049,000-5,472,000-2,445,277-1,409,3421,040,000
Earnings
Mar 17, 2025

Profile

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.
URL
https://www.tissueregenix.com/
IPO date
Dec 21, 2006
Employees
85
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122016‑012015‑01
Income
Revenues
29,493
48.43%
19,870
38.40%
14,358
11.91%
Cost of revenue
29,887
21,483
17,340
Unusual Expense (Income)
NOPBT
(394)
(1,612)
(2,983)
NOPBT Margin
Operating Taxes
(12)
(188)
(114)
Tax Rate
NOPAT
(382)
(1,424)
(2,868)
Net income
(1,713)
-21.71%
(2,188)
-37.21%
(3,484)
-64.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
74
BB yield
-0.20%
Debt
Debt current
642
943
87
Long-term debt
12,163
7,045
5,780
Deferred revenue
Other long-term liabilities
2,674
2,484
Net debt
8,155
3,042
176
Cash flow
Cash from operating activities
1,040
(1,409)
(2,445)
CAPEX
(324)
(885)
(1,488)
Cash from investing activities
(837)
(885)
(1,488)
Cash from financing activities
(1,512)
1,104
145
FCF
(2,929)
(3,056)
(3,383)
Balance
Cash
4,650
4,946
5,692
Long term investments
Excess cash
3,175
3,952
4,974
Stockholders' equity
(95,357)
(85,228)
(73,479)
Invested Capital
134,107
118,450
103,949
ROIC
ROCE
EV
Common stock shares outstanding
70,427
70,345
70,331
Price
0.52
-7.96%
0.57
5.61%
0.54
9,807.41%
Market cap
36,622
-7.86%
39,745
5.63%
37,627
15,566.54%
EV
73,623
42,079
37,101
EBITDA
392
(691)
(2,189)
EV/EBITDA
187.83
Interest
1,138
671
503
Interest/NOPBT